NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both marketed as NAD+ precursors, and both show up constantly in longevity discussions — but they’re not the same molecule, and the research comparing them is more nuanced than “pick one.”
Informational only — not medical advice.*
Where They Sit in the NAD+ Pathway
NAD+ (nicotinamide adenine dinucleotide) is synthesized through a multi-step pathway. NR sits one step earlier in the pathway than NMN — NR is converted into NMN (via the enzyme NRK), which is then converted into NAD+ (via the enzyme NMNAT). Both are precursors; NMN is simply one step closer to the end product.
Absorption Research
A key question in the comparison is how each molecule is absorbed and transported. NMN’s absorption pathway has been a subject of ongoing research interest, including the identification of a dedicated transporter (Slc12a8) in some tissue studies. NR has a longer research history in human trials and a somewhat more established absorption profile as a result, though the field is evolving quickly for both molecules.
What the Research Has Actually Studied
- Both have been studied for their effect on blood NAD+ levels, with human trials showing measurable increases for each.
- Direct head-to-head human comparisons between NMN and NR are limited — most existing research studies them separately, which makes direct comparison difficult.
- Dosing protocols vary significantly across studies for both molecules, complicating cross-study comparison.
Practical Takeaway
Neither molecule has a clearly established research advantage over the other for most outcomes studied — the field is still developing. Sierra Life Sciences manufactures NMN Cellular Performance for those interested in this pathway. Talk to your healthcare provider about what’s appropriate for your situation.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.